- Home
- KITT vs MBRX Comparison
KITT vs MBRX Comparison
Compare KITT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KITT
- MBRX
- Stock Information
- Founded
- KITT 2014
- MBRX 2015
- Country
- KITT United States
- MBRX United States
- Employees
- KITT N/A
- MBRX N/A
- Industry
- KITT Industrial Machinery/Components
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- KITT Industrials
- MBRX Health Care
- Exchange
- KITT Nasdaq
- MBRX Nasdaq
- Market Cap
- KITT 6.3M
- MBRX 7.0M
- IPO Year
- KITT N/A
- MBRX 2016
- Fundamental
- Price
- KITT $0.91
- MBRX $1.85
- Analyst Decision
- KITT
- MBRX Strong Buy
- Analyst Count
- KITT 0
- MBRX 3
- Target Price
- KITT N/A
- MBRX $31.00
- AVG Volume (30 Days)
- KITT 3.2M
- MBRX 47.1K
- Earning Date
- KITT 11-12-2024
- MBRX 11-08-2024
- Dividend Yield
- KITT N/A
- MBRX N/A
- EPS Growth
- KITT N/A
- MBRX N/A
- EPS
- KITT N/A
- MBRX N/A
- Revenue
- KITT $2,399,852.00
- MBRX N/A
- Revenue This Year
- KITT $980.78
- MBRX N/A
- Revenue Next Year
- KITT N/A
- MBRX N/A
- P/E Ratio
- KITT N/A
- MBRX N/A
- Revenue Growth
- KITT N/A
- MBRX N/A
- 52 Week Low
- KITT $0.85
- MBRX $0.40
- 52 Week High
- KITT $28.76
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- KITT 37.21
- MBRX 34.90
- Support Level
- KITT $1.00
- MBRX $1.81
- Resistance Level
- KITT $1.08
- MBRX $3.10
- Average True Range (ATR)
- KITT 0.12
- MBRX 0.25
- MACD
- KITT -0.00
- MBRX -0.08
- Stochastic Oscillator
- KITT 0.88
- MBRX 6.40
About KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops autonomous robots for the ocean industries. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing of related software to both the commercial and defense business sectors. Nauticus' services provide customers with the necessary data collection, analytics, and subsea manipulation capabilities to support and maintain assets while reducing their operational footprint, operating cost, and greenhouse gas emissions, to improve offshore health, safety, and environmental exposure.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.